Bruce L. Levine

faculty photo
Barbara and Edward Netter Professor in Cancer Gene Therapy
Abramson Cancer Center of the University of Pennsylvania (Member), Abramson Cancer Center of the University of Pennsylvania (Member)
Deputy Director - Technology Innovation and Assessment, Center for Cellular Immunotherapies, University of Pennsylvania Department of Pathology and Laboratory Medicine, Perelman School of Medicine
Founding Director, Clinical Cell and Vaccine Production Facility, University of Pennsylvania Department of Pathology and Laboratory Medicine, Perelman School of Medicine and Abramson Cancer Center
Department: Pathology and Laboratory Medicine

Contact information
Center for Cellular Immunotherapies
Smilow 8-114
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-746-1481
Graduate Group Affiliations
B.A. (Major-Biology, Minor-History)
The University of Pennsylvania , 1984.
Ph.D. (Immunology and Infectious Diseases)
The Johns Hopkins University, 1992.
Permanent link

Description of Research Expertise

Immunology, Cell and Gene Therapy

Description of Other Expertise

Good Manufacturing Practices

Description of Itmat Expertise

Dr. Levine's interests include cell, gene, and biologic therapy clinical trial development, manufacturing, and testing and lymphocyte growth, activation and senescence.

Selected Publications

Garfall Alfred L, Dancy Ehren K, Cohen Adam D, Hwang Wei-Ting, Fraietta Joseph A, Davis Megan M, Levine Bruce L, Siegel Don L, Stadtmauer Edward A, Vogl Dan T, Waxman Adam, Rapoport Aaron P, Milone Michael C, June Carl H, Melenhorst J Joseph: T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood advances 3(19): 2812-2815, Oct 2019.

Chong Elise A, Levine Bruce L, Grupp Stephan A, Davis Megan M, Siegel Don L, Maude Shannon L, Gladney Whitney L, Frey Noelle V, Porter David L, Hwang Wei-Ting, Chong Emeline R, June Carl H, Schuster Stephen J: CAR T cell viability release testing and clinical outcomes: is there a lower limit? Blood Sep 2019.

Wang Kan, Liu Y I, Li Junxuan, Wang Ben, Bishop Reid, White Chip, DAS Amritava, Levine Aaron D, Ho Linda, Levine Bruce L, Fesnak Andrew D: A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies. Cytotherapy Aug 2019.

Haas Andrew R, Tanyi Janos L, O'Hara Mark H, Gladney Whitney L, Lacey Simon F, Torigian Drew A, Soulen Michael C, Tian Lifeng, McGarvey Maureen, Nelson Anne Marie, Farabaugh Caitlin S, Moon Edmund, Levine Bruce L, Melenhorst J Joseph, Plesa Gabriela, June Carl H, Albelda Steven M, Beatty Gregory L: Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Molecular therapy : the journal of the American Society of Gene Therapy Jul 2019.

Cohen Adam D, Garfall Alfred L, Stadtmauer Edward A, Melenhorst J Joseph, Lacey Simon F, Lancaster Eric, Vogl Dan T, Weiss Brendan M, Dengel Karen, Nelson Annemarie, Plesa Gabriela, Chen Fang, Davis Megan M, Hwang Wei-Ting, Young Regina M, Brogdon Jennifer L, Isaacs Randi, Pruteanu-Malinici Iulian, Siegel Don L, Levine Bruce L, June Carl H, Milone Michael C: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. The Journal of Clinical Investigation 130: 126397, Mar 2019.

Stein Andrew M, Grupp Stephan A, Levine John E, Laetsch Theodore W, Pulsipher Michael A, Boyer Michael W, August Keith J, Levine Bruce L, Tomassian Lori, Shah Sweta, Leung Mimi, Huang Pai-Hsi, Awasthi Rakesh, Mueller Karen Thudium, Wood Patricia A, June Carl H: Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells. CPT: pharmacometrics & systems pharmacology Mar 2019 Notes: ePub ahead of print doi: 10.1002/psp4.12388.

Harrison Richard P, Zylberberg Ezequiel, Ellison Simon, Levine Bruce L: Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. Cytotherapy 21(2): 224-233, Feb 2019.

Mueller Karen T, Waldron Edward R, Grupp Stephan A, Levine John E, Laetsch Theodore W, Pulsipher Michael A, Boyer Michael W, August Keith, Hamilton Jason, Awasthi Rakesh, Stein Andrew M, Sickert Denise, Chakraborty Abhijit, Levine Bruce L, June Carl H, Tomassian Lori, Shah Sweta, Leung Mimi, Taran Tetiana, Wood Patricia A, Maude Shannon L: Clinical Pharmacology of Tisagenlecleucel in B-Cell Acute Lymphoblastic Leukemia. Clinical Cancer Research 24(24): 6175, December 2018.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ: Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine 24(10): 1499-1503, October 2018.

Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, Melenhorst JJ, Milone MC: Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells. Cancer Immunol Res. 6(9): 100-1109, September 2018 Notes: doi: 10.1158/2326-6066.CIR-17-0405. [Epub ahead of print]

back to top
Last updated: 11/20/2019
The Trustees of the University of Pennsylvania